IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, Friday announced the grant of non-qualified stock options to two newly hired employees on January 30, 2025.
The total grant was for 62,800 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan. These stock options were granted as an inducement for the individuals to join IDEAYA, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $23.88 per share, the closing price of IDEAYA's stock on the date of grant.
The options have a 10-year term and will vest over four years, with 25 percent vesting on the first anniversary and the remaining 75 percent vesting in monthly installments over the next three years, subject to continued service.
IDEAYA Biosciences focuses on discovering and developing targeted therapeutics in oncology, applying a precision medicine approach to identify patient populations that will benefit most from its therapies.
Currently, IDYA is trading at $24.40, up by 2.18 percent on Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.